Literature DB >> 25464491

Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure.

Kaspar Broch1, Arne K Andreassen2, Thor Ueland3, Annika E Michelsen3, Wenche Stueflotten2, Pål Aukrust4, Svend Aakhus2, Lars Gullestad5.   

Abstract

BACKGROUND: Elevated levels of soluble ST2 (sST2) are associated with adverse outcome in heart failure. A change in sST2 levels has also been shown to presage outcome. In vitro, ST2 expression is induced by myocardial stress and pro-inflammatory stimuli. The determinants of sST2 levels in vivo, and how they vary with clinical status over time, have not been well described. In a cohort of patients with non-ischemic heart failure, we aimed to assess the association between sST2-levels and hemodynamic parameters reflecting right and left ventricular pre- and afterload, and how these vary with time and clinical status.
METHODS: We prospectively recruited 102 patients with a left ventricular ejection fraction of 26 ± 10% and a diagnosis of idiopathic dilated cardiomyopathy based on patient history, clinical examination, echocardiography and coronary angiography. Patients went through extensive baseline work-up and were re-examined after one year. Subsequently, heart transplantations and deaths were recorded. Determinants of sST2 were analyzed at baseline and after one year. Soluble ST2 was measured with a highly sensitive immunoassay.
RESULTS: Soluble ST2 levels were associated with hemodynamic parameters, but these associations were attenuated with clinical improvement. Soluble ST2 was elevated in patients with severe symptoms, but did not vary with etiology, viral presence or the amount of myocardial fibrosis. Heart rate and right atrial pressure remained independent predictors of sST2 on multiple regression analysis.
CONCLUSIONS: Our results imply that in non-ischemic heart failure, sST2 reflects hemodynamic stress rather than pathogenic processes in the myocardium.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; Etiology; Hemodynamics; Prognosis; ST2

Mesh:

Substances:

Year:  2014        PMID: 25464491     DOI: 10.1016/j.ijcard.2014.11.003

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

1.  The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy.

Authors:  Hilde M Norum; Kaspar Broch; Annika E Michelsen; Ida G Lunde; Tove Lekva; Aurelija Abraityte; Christen P Dahl; Arnt E Fiane; Arne K Andreassen; Geir Christensen; Svend Aakhus; Pål Aukrust; Lars Gullestad; Thor Ueland
Journal:  J Cardiovasc Transl Res       Date:  2017-05-04       Impact factor: 4.132

2.  Results of comprehensive diagnostic work-up in 'idiopathic' dilated cardiomyopathy.

Authors:  Kaspar Broch; Arne K Andreassen; Einar Hopp; Trond P Leren; Helge Scott; Fredrik Müller; Svend Aakhus; Lars Gullestad
Journal:  Open Heart       Date:  2015-10-09

3.  Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy.

Authors:  Santiago Roura; Carolina Gálvez-Montón; David de Gonzalo-Calvo; Ana Gámez Valero; Paloma Gastelurrutia; Elena Revuelta-López; Cristina Prat-Vidal; Carolina Soler-Botija; Aida Llucià-Valldeperas; Isaac Perea-Gil; Oriol Iborra-Egea; Francesc E Borràs; Josep Lupón; Vicenta Llorente-Cortés; Antoni Bayes-Genis
Journal:  J Cell Mol Med       Date:  2017-05-29       Impact factor: 5.310

4.  Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device.

Authors:  Cheyenne C S Tseng; Manon M H Huibers; Lonneke H Gaykema; Erica Siera-de Koning; Faiz Z Ramjankhan; Alan S Maisel; Nicolaas de Jonge
Journal:  Eur J Clin Invest       Date:  2018-02-02       Impact factor: 4.686

5.  Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy.

Authors:  Aurelija Abraityte; Ida G Lunde; Erik T Askevold; Annika E Michelsen; Geir Christensen; Pål Aukrust; Arne Yndestad; Arnt Fiane; Arne Andreassen; Svend Aakhus; Christen P Dahl; Lars Gullestad; Kaspar Broch; Thor Ueland
Journal:  Sci Rep       Date:  2017-06-14       Impact factor: 4.379

6.  The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure.

Authors:  David Binas; Hanna Daniel; Anette Richter; Volker Ruppert; Klaus-Dieter Schlüter; Bernhard Schieffer; Sabine Pankuweit
Journal:  Open Heart       Date:  2018-02-26

Review 7.  Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Larisa Anghel; Radu Sascău; Ioana Mădălina Zota; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

8.  GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.

Authors:  Stefan Stojkovic; Alexandra Kaider; Lorenz Koller; Mira Brekalo; Johann Wojta; Andre Diedrich; Svitlana Demyanets; Thomas Pezawas
Journal:  J Cell Mol Med       Date:  2018-02-04       Impact factor: 5.295

9.  Exercise-induced Changes in Soluble ST2 Concentrations in Marathon Runners.

Authors:  Vincent L Aengevaeren; Roland R J VAN Kimmenade; Maria T E Hopman; Niels VAN Royen; James V Snider; James L Januzzi; Keith P George; Thijs M H Eijsvogels
Journal:  Med Sci Sports Exerc       Date:  2019-03       Impact factor: 5.411

10.  Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation.

Authors:  Zefeng Wang; Liting Cheng; Junmeng Zhang; Zhuo Liang; Ruiqing Dong; Fei Hang; Xinlu Wang; Ziyu Wang; Yongquan Wu; Jie Du
Journal:  Med Sci Monit       Date:  2020-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.